Roth Capital Positive on Palatin (PTN) Granting Bremelanotide Extension
Tweet Send to a Friend
Roth Capital reaffirms its Buy rating and $6 target price on Palatin Technologies Inc. (AMEX: PTN) after Palatin announced that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
